drugset / Trial / NCT01529112

A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments

NCT01529112 ↗

Phase 2 Completed 135 enrolled Eisai Inc. Quintiles, Inc. · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to compare the overall survival of patients receiving E7080 + Best Supportive Care (BSC) with those receiving placebo + Best Supportive Care.

Timeline

Start
2011-11
Primary completion
2014-01-21
Completion
2015-06-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenvatinib Small molecule 24 mg Oral